NCT04018170View on ClinicalTrials.gov

Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

December 15, 2019

Study Completion Date

December 15, 2019

Conditions
Healthy
Interventions
DRUG

Study drug

oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg

DRUG

Placebo

oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets

Trial Locations (2)

06725

Severance Hospital, Seoul

Unknown

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical
All Listed Sponsors
lead

JW Pharmaceutical

INDUSTRY

NCT04018170 - Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers | Biotech Hunter | Biotech Hunter